09:46 AM EST - BioVaxys Technology Corp : Announced the United States Patent and Trademark Office has issued BioVaxys U.S. Patent No. 12,042,537. for inducing an antibody immune response from a low dose volume delivery of a B-cell epitope formulated with DPX™. This Patent was recently allowed in Japan and is currently pending in the European Union. DPX™ is a proprietary lipid-based delivery platform with no aqueous component that can be formulated with a range of packaged antigens, proteins, peptides, mRNA, or small molecules. Its unique "no release" mechanism of action allows antigen presenting cells to be attracted to the injection site, facilitating a robust and long-duration immune response. BioVaxys Technology Corp
shares C.BIOV are trading unchanged at $0.07.
